Table 1.
Biochemical Risk Markers | |
---|---|
Traditional risk factors Age | — |
Male gender | — |
Hypertension | — |
Left ventricular hypertrophy | — |
Smoking | — |
Diabetes mellitus | HbA1c [52], glucose [53] |
Dyslipidemia | Cholesterol [28], Lp(a) [189] |
Novel risk and/or uremia-related risk factors | |
Inflammation | IL-6 [37], IL-18 [38], S-albumin [39], WBC [40], fibrinogen [41], hyaluronan [42], MPO [43], CRP [44], PTX3 [45] |
Oxidative stress | MPO [43], plasmalogens [127], oxLDL [125], AOPP [126] |
Endothelial dysfunction | PTX3 [45], ADMA [79], tHcys [47], U-albumin [87], VCAM [97] |
Protein-energy wasting | S-albumin [39], S-creatinine [39], prealbumin [50] |
Sympathetic activation | Norepinephrine [51] |
Coagulation/fibrinolysis disorders | Fibrinogen [41] |
Insulin resistance | HOMA [54] |
Genetics/epigenetics | SNPs [188], telomere attrition [190], DNA-methylation [198] |
Vascular calcification | PO4 [147], Ca [148], PTH [148], fetuin-A [156[, OPG [162], OPN [163] |
Classical uremic toxins | S-creatinine [39], P-cresol [76] |
New uremic toxins | Proteomics [183] |
Volume | NT-pro-BNP [48], troponin-T [49] |
Subclinical hypothyroidism | fT3 [172], T3 [174] |
Adipokines | Leptin [58], visfatin [59], adiponectin [66] |
Anemia | Hemoglobin [55] |
HbA1c, glycated hemoglobin; Lp(a), lipoprotein(a); IL, interleukin; WBC, white blood cell count; MPO, myeloperoxidase; CRP, C-reactive protein; PTX3, pentraxin-3; ADMA, asymmetric dimethylarginine; oxLDL, oxidized LDL; AOPP, advanced oxidation protein products; tHcys, homocystine; U-alb, urinary albumin excretion; VCAM, vascular cell adhesion molecule; HOMA, homeostasis model assessment method; SNP, single nucleotide polymorphism; PTH, parathyroid hormone; OPG, osteoprotegerin; OPN, osteopontin; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; T3, triiodothyronine.